Physician profile
Brooke Peyton
NPI 1184109787
$1,647.04
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,251 · 2022: $192 · 2023: $170 · 2024: $33.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $203.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $411.94 | 2021-2024 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $280.67 | 2021-2022 | |
| Abbvie INC. | $276.55 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $209.29 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $133.53 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $80.31 | 2021 | |
| Lundbeck LLC | $72.05 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.78 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $31.93 | 2021 | |
| Corium, LLC | $28.37 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $27.78 | 2021 | |
| Indivior INC. | $15.95 | 2021 | |
| Ironshore Pharmaceuticals INC. | $14.09 | 2022 | |
| Eisai INC. | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Peyton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.